Search Results
Your search for ,twO matches 12066 pages
Showing 1001 - 1050EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence
A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...
Lung ART Trial: End of the Road for Postoperative Radiotherapy?
Lung cancer is a significant global health issue, remaining the leading cause of cancer-related deaths with 2.1 million new cases and 1.8 million deaths. Complete surgical resection is the treatment of choice for operable early-stage non–small cell lung cancer (NSCLC) and resectable stage IIIA...
Can AI Help Identify Kidney Tumors That May Respond to Immunotherapy?
Clear cell renal cell carcinoma is the most common type of kidney cancer, comprising 80% of all malignant tumors found within the kidney. Although some clear cell renal cell carcinoma tumors are sensitive to immune checkpoint inhibitors, currently, there are no measures to predict whether a tumor...
How War Has Disrupted the Management of Patients With Breast Cancer in Sudan
Sudan is the third-largest country in Africa, spanning 1,886,068 km2. It is situated in an area surrounded by North Africa, Sub-Saharan Africa, and the Middle East. As of 2020, Sudan had a population of approximately 43.8 million people, with a significant proportion being younger than age 15....
Expert Point of View: Michail Ignatiadis, MD, PhD and Stephen R.D. Johnston, MD, PhD
The September 2023 European Society for Medical Oncology (ESMO) Virtual Plenary presentation of the NATALEE health-related quality-of-life (QOL) findings was discussed by Michail Ignatiadis, MD, PhD, and Stephen R.D. Johnston, MD, PhD. Dr. Ignatiadis is Director of the Breast Medical Oncology...
NATALEE Trial: Quality of Life Maintained for Many Patients Treated With Ribociclib for Early-Stage Breast Cancer
An analysis of patient-reported outcomes in the adjuvant phase III NATALEE trial of ribociclib plus endocrine therapy in early-stage breast cancer showed maintenance of health-related quality of life (QOL), as determined by a number of factors. For patients receiving the inhibitor of...
IVIG May Reduce Infection Risk Among Patients With Multiple Myeloma Receiving Anti-BCMA Therapy
Although the 5-year survival rate for multiple myeloma has increased over the past 2 decades—from about 35% in 2000 to approximately 62% in 2015—due to more effective therapies, the cancer remains incurable. According to the American Cancer Society, this year, nearly 36,000 individuals will be...
Adjuvant Canakinumab in Completely Resected NSCLC
In the phase III CANOPY-A trial reported in Journal of Clinical Oncology, Edward B. Garon, MD, and colleagues found that adjuvant therapy with the interleukin (IL)-1β pathway inhibitor canakinumab did not significantly improve disease-free survival vs placebo in patients with completely resected...
Guideline Update Reflects Recent Surge of New Data in Systemic Therapy for Melanoma
A guideline update on systemic treatment for melanoma offers new guidance in several areas, including the selection of front-line therapy for patients with metastatic disease with and without BRAF mutations, treatment of patients with earlier-stage disease in the adjuvant setting, and emerging...
ASCO and State Affiliates Wrap Up Successful State Sessions
After a fast-paced first half of the year, most state legislatures across the 50 states and Washington, DC, have adjourned for the year. The Association for Clinical Oncology (ASCO) and State Affiliates successfully collaborated to advance many shared 2023 state advocacy priorities, including those ...
NUC-1031/Cisplatin Fails to Improve Outcomes in Advanced Biliary Tract Cancer
As a first-line treatment for advanced biliary tract cancer, an experimental formulation of gemcitabine, NUC-1031, given with cisplatin failed to improve outcomes over standard gemcitabine/cisplatin in the global phase III NuTide:121 trial.1 “NuTide:121 has not advanced the field in biliary tract...
Checkpoint Inhibitors Offer Limited Benefit in EGFR-Mutated Lung Cancer After Disease Progression
In advanced non–small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR), the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study ...
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
HER3-Expressing Metastatic Breast Cancer: Patritumab Deruxtecan in Previously Treated Patients
In a Japanese-U.S. phase I/II trial (U31402-A-J101) reported in the Journal of Clinical Oncology, Ian E. Krop, MD, PhD, and colleagues found that the HER3-targeted antibody-drug conjugate patritumab deruxtecan (HER3-DXd) produced durable responses in previously treated patients with HER3-expressing ...
Individualized SABR for Lung Tumors
In a phase II study (iSABR) reported in JAMA Oncology, Gensheimer et al found that individualized stereotactic ablative radiotherapy (SABR) for up to four lung cancer tumors was associated with a high degree of local control and the ability to minimize radiation doses. Study Details Two hundred and ...
KRAS G12C Inhibitors: Durability of Response, Efficacy in Combination, in NSCLC
At the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, the benefit of two KRAS G12C inhibitors in advanced non–small cell lung cancer (NSCLC) was upheld by the 2-year follow-up analysis of adagrasib in the KRYSTAL-11 and the early-phase CodeBreaK 101...
Dendritic Cell Vaccine Plus Stem Cell Transplant for Multiple Myeloma
Although the development of new therapies for multiple myeloma has significantly improved response rates and outcomes for patients with the blood cancer, most patients eventually relapse, including those who initially achieved remission. A phase I study is investigating whether a dendritic cell...
Small Breast Cancer: Omission of Axillary Surgery vs Sentinel Lymph Node Biopsy
In a noninferiority phase III trial (SOUND) reported in JAMA Oncology, Gentilini et al found that no axillary surgery was noninferior to sentinel lymph node biopsy (SLNB) in terms of distant disease–free survival among patients with small breast cancer and negative findings on preoperative...
Chemotherapy Shortages Ongoing, According to New Survey
The National Comprehensive Cancer Network® (NCCN®) has released a follow-up survey on the ongoing chemotherapy shortages, refreshing findings they originally shared in June 2023. According to their results, 72% of the cancer centers surveyed continue to experience a shortage of carboplatin, and 59% ...
From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...
Isa-KrD for Transplant-Eligible and -Ineligible High-Risk Newly Diagnosed Multiple Myeloma
In an interim analysis of a German phase II trial (MMG-CONCEPT) reported in the Journal of Clinical Oncology, Leypoldt et al found that Isa-KrD (isatuximab, carfilzomib, lenalidomide, and dexamethasone) produced high rates of measurable residual disease (MRD) negativity newly diagnosed patients...
Circulating Tumor DNA Identified in Breast Milk From Women With Breast Cancer: First Results Published
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum contains circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in...
Liquid Biopsies May Be Predictive of Cancer Recurrence Following Chemoradiation in Patients With Cervical Cancer
Two liquid biopsy tests designed to detect the human papillomavirus (HPV) in the blood may accurately identify patients at high risk of cervical cancer recurrence following the completion of chemoradiation, according to new findings presented by Han et al at the 2023 American Society for Radiation...
Precision Medicine Navigators May Increase Genomic Testing Rates Among Black Patients With Prostate Cancer
The presence of precision medicine navigators may increase the likelihood that patients with prostate cancer, especially Black patients, will receive genomic testing that may help predict the severity of their disease and guide treatment, according to findings presented by Allen et al at the 2023...
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation: FABREC Trial
In a first-of-its-kind study, patients with breast cancer who underwent implant-based breast reconstruction immediately following a mastectomy reported that getting fewer, higher doses of radiation was just as effective as standard radiation, did not increase side effects, and saved them time and...
Stereotactic Radiotherapy for Patients With Primary RCC Unsuitable for Surgery: FASTRACK II
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests. A multi-institutional phase II study—TransTasman Radiation Oncology Group (TROG) FASTRACK II—found 100% local...
Prophylactic Radiation for High-Risk Asymptomatic Bone Metastases
In a phase II trial reported in the Journal of Clinical Oncology, Erin F. Gillespie, MD, MPH, and colleagues found that prophylactic radiotherapy in patients with high-risk asymptomatic bone metastases from solid tumors reduced the risk of skeletal-related events compared with standard of care. A...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Ambulatory Thromboprophylaxis in Patients With Lung and Gastrointestinal Cancers
In an Australian phase III trial (TARGET-TP) reported in JAMA Oncology, Alexander et al found that ambulatory thromboprophylaxis reduced the risk of thromboembolic events in patients starting systemic therapy for lung or gastrointestinal cancer who were at elevated risk of thrombosis. Study ...
Unconscious Gender Biases and Discrimination Lead to Suboptimal Care for Women
Gender inequalities and discrimination may adversely impact women’s rights and opportunities to avoid cancer risk factors and impede their ability to seek and obtain timely diagnoses and quality cancer care, according to The Lancet Commission on Women, Power, and Cancer published by Ginsburg et al...
Using Whole-Body Imaging Agent to Predict Response to Treatment in HER2-Positive Metastatic Breast Cancer
The novel imaging agent gallium (Ga)-68–ABY-025 may help to predict early metabolic response to HER2-targeted treatment in patients with HER2-positive metastatic breast cancer, according to a recent study published by Alhuseinalkhudhur et al in The Journal of Nuclear Medicine. These findings...
First-Line Dabrafenib/Trametinib in Pediatric BRAF V600–Mutated Low-Grade Glioma
In a phase II trial reported in The New England Journal of Medicine, Eric Bouffet, MD, and colleagues found that the combination of dabrafenib and trametinib produced a higher objective response rate vs standard chemotherapy in the first-line treatment of pediatric patients with low-grade glioma...
Mutations in 11 Genes May Be Associated With Aggressive Prostate Cancer
Researchers have singled out mutations in 11 genes associated with aggressive types of prostate cancer, according to a novel study published by Darst et al in JAMA Oncology. The new findings may lead to improvements in diagnosis and treatment. Background Currently, oncologists use genetic tests to...
Carfilzomib and Lenalidomide–Based Therapy in Primary Plasma Cell Leukemia
In a European phase II trial (EMN12/HOVON-129) reported in The Lancet Oncology, van de Donk et al found that the incorporation of carfilzomib and lenalidomide into induction, consolidation, and maintenance therapies was associated with good outcomes in both younger and older patients with primary...
FDA Approves Bosutinib for Pediatric Patients With Chronic Myelogenous Leukemia
On September 26, the U.S. Food and Drug Administration (FDA) approved bosutinib (Bosulif) for pediatric patients aged 1 year and older with chronic-phase, Philadelphia chromosome–positive chronic myelogenous leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. The FDA ...
Do Checkpoint Inhibitors Show Benefit in EGFR-Mutated NSCLC After Progression?
In patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations, the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study of Lung Cancer 2023 ...
Hypofractionated vs Conventional Fractionated Proton Radiotherapy After Mastectomy for Breast Cancer
In a phase II trial (MC1631) reported in The Lancet Oncology, Robert W. Mutter, MD, and colleagues found that the 24-month complication rate associated with hypofractionated proton postmastectomy radiotherapy (PMRT) was not noninferior to standard fractionated PMRT in patients undergoing mastectomy ...
Exposure to PFAS and Phenols May Be Linked to Cancer Risk
Investigators have discovered that significantly higher levels of endocrine-disrupting chemicals such as per- and poly-fluoroalkyl substances (PFAS) and phenols may be present in patients with breast, ovarian, skin, and endometrial cancers, according to a recent study published by Cathey et al in...
City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies
Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine (CIRM) to support three novel phase I clinical trials evaluating innovative cell and gene therapies for patients with HIV, acute myeloid leukemia (AML), and severe aplastic anemia. Beckman ...
27th Cancer Leadership Awards Recipients Announced by Friends of Cancer Research
Friends of Cancer Research recently announced its 2023 Cancer Leadership Awards honorees: Commissioner of the U.S. Food and Drug Administration (FDA), Robert Califf, MD, and Congresswoman Debbie Dingell (D-MI). Dr. Califf, recognized for his work in the field of cardiology and the broader medical ...
From Texas to Sweden, Medical Oncologist Gil Morgan, MD, Enjoys Connecting the Cancer Community
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Gil Morgan, MD, a clinical oncologist formerly at the Division of Medical and Radiation Oncology at Skåne University Hospital, Lund, Sweden and now full-time Director of the OncoAlert...
Particulate Matter Concentrations and Incidence of Breast Cancer
Investigators have found that residing in areas with high levels of particulate air pollution may be associated with an increased risk of developing breast cancer, according to a recent study published by White et al in the Journal of the National Cancer Institute. Background Particulate matter...
SIO and ASCO Partner to Develop Integrative Oncology Care Recommendations for Anxiety and Depression in Patients With Cancer
The Society for Integrative Oncology (SIO) and ASCO have partnered to develop a new guideline on integrative oncology care of symptoms of anxiety and depression in adults with cancer. The guideline reviews the evidence for a range of integrative approaches, including mindfulness-based...
ASCO Releases Rapid Recommendation Update on Use of Olanzapine to Treat Cancer-Related Cachexia
ASCO recently released a new rapid recommendation update that addresses the use of olanzapine to treat cancer-related cachexia, a topic originally addressed in its 2020 guideline on the management of cancer cachexia in adults with advanced cancer.1,2 At that time, there was insufficient evidence to ...
Accelerated Approval Granted for Talquetamab-tgvs in Treatment of Relapsed or Refractory Multiple Myeloma
On August 9, 2023, the bispecific GPRC5D (G protein–coupled receptor, class C, group 5)-directed CD3 T-cell engager talquetamab-tgvs was granted accelerated approval by the U.S. Food and Drug Administration for treatment of adults with relapsed or refractory multiple myeloma who have received at...
More on Biliary Tract Cancer From ASCO 2023: Focus on Zanidatamab
The HER2-targeting bispecific antibody zanidatamab generated rapid and durable responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer previously treated with gemcitabine, investigators from the global phase IIb HERIZON-BTC-01 study reported at...
More on Renal Cell Carcinoma From ASCO 2023: Focus on Atezolizumab Plus Cabozantinib vs Cabozantinib Alone
The addition of the monoclonal antibody atezolizumab to the tyrosine kinase inhibitor cabozantinib failed to improve progression-free survival and overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma (previously treated with an immune checkpoint inhibitor) in the...
Highlights in Cancer and Aging From the 2023 ASCO Annual Meeting
The 2023 ASCO Annual Meeting again demonstrated the Society’s commitment to improving cancer care for all older adults. Pertinent questions related to treatment and management in this population were addressed in educational and oral abstract sessions, clinical science symposia, and case-based...
Understanding the Treatment of Waldenström’s Macroglobulinemia
Waldenström’s macroglobulinemia is a rare and incurable low-grade B-cell lymphoproliferative disease defined by specific genotypic subtypes that have implications for treatment response and long-term outcomes. Treatment—and there is no established standard—is mainly focused on controlling symptoms...
Distributing Scarce Cancer Drugs Legally and Ethically
During the COVID-19 pandemic, many medical specialties became familiar with supply chain interruptions resulting in drug, equipment, and personnel scarcity. Intensive care unit beds, staff, and essential medicines were at times in short supply. The federal government, individual states, and...
